Fintel reports that on October 3, 2025, D. Boral Capital maintained coverage of UroGen Pharma (NasdaqGM:URGN) with a Buy ...
Fintel reports that on September 29, 2025, D. Boral Capital maintained coverage of Medicus Pharma (NasdaqCM:MDCX) with a Buy recommendation. Analyst Price Forecast Suggests 662.74% Upside As of ...
The pharmaceutical industry is caught between a rock and a hard place. If the pricing concerns sparked by the recently enacted Inflation Reduction Act are not enough, the Federal Trade Commission has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback